Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Fineline Cube Feb 27, 2026
Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Fineline Cube Feb 27, 2026
Company Deals

Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream

Fineline Cube Sep 19, 2024

US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a...

Company Drug

MSD’s Keytruda Secures FDA Approval for First-Line Mesothelioma Treatment in Combination with Chemotherapy

Fineline Cube Sep 19, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that the US Food and...

Company Drug

AstraZeneca’s Fasenra Secures FDA Nod for EGPA Treatment, Strengthening Rare Disease Portfolio

Fineline Cube Sep 19, 2024

UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced that the US Food and...

Company Deals

Fidson Healthcare Partners with Chinese Entities to Establish Drug Plant in Nigeria

Fineline Cube Sep 19, 2024

Nigeria-based pharmaceutical manufacturer Fidson Healthcare Plc has entered into a strategic partnership with Jiansu Aidea...

Company Deals

MGI Tech Joins Forces with Dasa to Enhance Precision Medicine in Brazil Through Advanced Genomic Sequencing

Fineline Cube Sep 19, 2024

MGI Tech Co., Ltd, a leading gene sequencing company based in China, has announced a...

Company Drug

AstraZeneca’s Tagrisso Achieves Milestones in Phase III LAURA Study for EGFR-mutated NSCLC at ESMO 2024

Fineline Cube Sep 19, 2024

Global pharmaceutical company AstraZeneca (AZ, NASDAQ: AZN, LON: AZN) has reported updated results from the...

Company Drug

Keymed Biosciences’ Stapokibart Receives First Prescription in China for IL-4Rα Targeting Therapy

Fineline Cube Sep 19, 2024

China-based biotech company Keymed Biosciences Inc. (HKG: 2162) has reached a significant milestone with its...

Company Drug

Adagene’s ADG126 Shows Promising Results in Phase Ib/II Study for MSS CRC at ESMO 2024

Fineline Cube Sep 19, 2024

Adagene Inc. (NASDAQ: ADAG), a biopharmaceutical company dedicated to the discovery and development of innovative...

Company Drug

Transcenta’s Osemitamab Combo Therapy Shows Promising Results in G/GEJ Cancer Treatment at ESMO 2024

Fineline Cube Sep 19, 2024

Transcenta Holdings Ltd (HKG: 6628), a leading biopharmaceutical company, has announced updated positive results from...

Company Drug

I-Mab’s Plonmarlimab Receives Breakthrough Therapy Designation in China for R/R MAS Treatment

Fineline Cube Sep 19, 2024

China-based biopharmaceutical company I-Mab (NASDAQ: IMAB) has announced that its proprietary human granulocyte-macrophage colony-stimulating factor...

Company Deals

Altamira Therapeutics and Nuance Pharma Expand Bentrio’s Reach in Asia

Fineline Cube Sep 18, 2024

Swiss pharmaceutical firm Altamira Therapeutics Ltd (NASDAQ: CYTO) and its Chinese partner Nuance Pharma have...

Company Drug

MSD and Daiichi Sankyo’s Patritumab Deruxtecan Achieves Milestone in Phase III Lung Cancer Trial

Fineline Cube Sep 18, 2024

Global healthcare leaders Merck, Sharp & Dohme Inc.(MSD; NYSE: MRK), known as MSD outside the...

Company Drug

GSK’s Blenrep-BorDex Combo Earns Breakthrough Therapy Designation in China for Multiple Myeloma

Fineline Cube Sep 18, 2024

The UK-based pharmaceutical colossus, GSK (LON: GSK, NYSE: GSK), has secured a Breakthrough Therapy Designation...

Company Drug

AstraZeneca’s Imfinzi-Imjudo Combo Sets New Longevity Benchmark in Liver Cancer Treatment

Fineline Cube Sep 18, 2024

UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has achieved a significant milestone with its...

Company Drug

BeiGene’s Tislelizumab Receives Israeli Nod for Oesophageal Cancer Treatment

Fineline Cube Sep 18, 2024

China-based biotech firm BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has been granted market...

Company Drug

Abbisko Therapeutics’ FGFR4 Inhibitor Irpagratinib Shows Positive Phase I Results at ESMO Congress

Fineline Cube Sep 18, 2024

Shanghai-based biotech firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has presented updates on its innovative...

Company Drug

Alphamab Oncology’s JSKN003 ADC Achieves Positive Safety and Efficacy Outcomes in Phase I Studies

Fineline Cube Sep 18, 2024

Alphamab Oncology (HKG: 9966), a leading player in the oncology space, has reported encouraging results...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Shows Promising Long-Term Survival Data at ESMO 202

Fineline Cube Sep 18, 2024

CStone Pharmaceuticals (HKG: 2616), a biopharmaceutical company based in China, has presented long-term treatment and...

Company Drug

Ascletis Pharma Initiates Phase I Trials for Monthly Subcutaneous and Daily Oral Obesity Treatment ASC30 in the US

Fineline Cube Sep 18, 2024

Ascletis Pharma Inc. (HKG: 1672), a biopharmaceutical company based in China, has announced the dosing...

Company

Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements

Fineline Cube Sep 18, 2024

Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...

Posts pagination

1 … 257 258 259 … 627

Recent updates

  • Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars
  • Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion
  • Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry
  • Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate
  • Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Company

Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion

Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.